U023 - Cellular Grafting in Vitiligo: Exciting Options!
Friday, March 1; 4:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Assess the role of cellular grafting in vitiligo
- Use modified cellular grafting technique in the surgical management of vitiligo
- Develop further modifications of cellular grafting of vitiligo
Surgical methods are emerging as an important solution for stable vitiligo refractory to medical treatment. Vitiligo surgery has gained steady importance with more and more improved techniques proving their effectiveness. Non-cultured epidermal cell suspension is emerging as the first line of surgical management of stable Vitiligo. During the last fifty years, the vitiligo surgery has evolved from tissue transplantation via cellular transplantation to reach a stage where the use of stem cells or immunomodulatory cells is contemplating. We would like to depict this wonderful journey of vitiligo surgery through this session.
- Hamzavi, Iltefat H., MD: AbbVie – A(NC); Bayer – I(Grants/Research Funding); Clinuvel – I(Fees); Eli Lilly and Company – I(Grants/Research Funding); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Global Vitiligo Foundation – B(NC); Hidradenitis Suppurativa Foundation – B(NC); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lenicura – I(EQ); Pfizer Inc. – I(Fees);
- Parsad, Davinder, MD: no financial relationships exist with commercial interests.
Dr. Hamzavi / Melanocyte-keratinocyte transplantation in vitiligo: Our Experience
Dr. Boon Kee / Optimized techniques for non-cultured cellular grafting in vitiligo
Dr. Parsad / Vitiligo surgery: Journey from tissue to cellular graft
All faculty / Panel Discussion